Diagnosis and Monitoring of Glaucoma with Optical Coherence Tomography Angiography
Diagnosis and Monitoring of Glaucoma with Optical Coherence Tomography Angiography
批准号:
9921397
负责人:
ROBERT N WEINREB
金额:
$50.37万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-05-01 至 2022-04-30
关键词:
3-DimensionalAgeAnatomyAngiographyAreaBlindnessBlood PressureBlood VesselsBruch&aposs basal membrane structureCardiovascular DiseasesCerebrovascular DisordersClassificationClinicalComplexDataDetectionDevelopmentDiagnosisDiseaseDocumentationEarly DiagnosisEvaluationEyeFloorFunctional disorderGanglion Cell LayerGlaucomaImaging technologyIndividualLaboratoriesLeadLongitudinal StudiesMeasurableMeasurementMeasuresMethodsMonitorOptic DiskOptical Coherence TomographyParticipantPathogenesisPatientsPerfusionPeripheralPrimary Open Angle GlaucomaQuality of lifeReportingResearchRetinaRoleScienceScotomaSeverity of illnessStructureSuspect GlaucomasTestingThickThinnessThrombophiliaTimeTissuesVasospasmVisionVisual FieldsWidthadvanced diseasecentral visual fieldclinical careclinical imagingcohortdensitydiagnostic accuracyeffective therapyfield studyfollow-upganglion cellhigh resolution imagingimaging modalityimprovedmaculanoveloptical imagingpreventrate of changeretina blood vessel structureretinal nerve fiber layer
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Optical coherence tomography angiography (OCTA) has been introduced recently as a non-
invasive, 3-dimensional imaging method to visualize and quantify microvasculature throughout the
retina. The proposed study evaluates the clinical utility of OCTA measurements compared to
standard structural measurements of the optic nerve head (ONH), retinal nerve fiber layer (RNFL)
and macula measured using the current clinical imaging standard, spectral domain optical coherence
tomography (SDOCT). Our research, and that of others, has shown that superficial retinal vessel
density (proportion of measured area composed of blood vessels) in the ONH region and macula is
less dense in primary open angle glaucoma (POAG) eyes than in healthy eyes. Moreover, diagnostic
accuracy is improved with increasing disease severity. Research from our laboratory suggests that the
diagnostic accuracy of vessel density is similar to that of SDOCT-measured RNFL thickness, and that
vessel density is reduced in retinal regions associated with localized visual field (VF) defects. These
cross-sectional results strongly suggest that OCTA measurements reflect damage to tissues relevant
to the pathophysiology of POAG. In a longitudinal study, moreover, the mean rate of change in
macula vessel density is significantly faster in POAG eyes than in glaucoma suspect or healthy eyes.
The current study provides a unique opportunity to extend for up to 8 years longitudinal OCTA data
that has already been collected from 250 eyes over 2 years, and to investigate vessel density change
over time in glaucoma suspect and POAG eyes, as well as to compare it to other imaging modalities
and glaucoma-related visual field change. The aims of the study are 1) to assess the longitudinal
temporal and topographic relationship in glaucoma between loss of superficial retinal vessel density,
loss of RNFL thickness, loss of neuroretinal rim width, and loss of ganglion cell complex (GCC)
thickness in glaucoma suspect and glaucoma eyes of varying disease severity, and 2) to assess the
longitudinal temporal and topographic relationship between superficial loss of macula and ONH
retinal vessel density, loss of RNFL thickness , loss of neuroretinal rim width, and loss GCC thickness
with the development and progression of central and peripheral VF defects in glaucoma. Comparison
of the time course of changes in vessel density relative to changes in RNFL thickness, neuroretinal
rim width, ganglion cell layer thickness and visual function will provide information about the
pathophysiology of glaucoma that can improve early detection and accurate monitoring of advanced
disease compared to currently available and widely accepted methods. Enhanced diagnosis and
detection of progression should lead to earlier and more effective treatment, thus reducing the rate of
disease worsening and preventing loss of vision-related quality of life (including blindness).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Diagnosis and Monitoring of Glaucoma with Optical Coherence Tomography Angiography
-
批准号:10615796
-
项目类别:
-
资助金额:$69.17万
-
财政年份:2018
-
负责人:ROBERT N WEINREB
-
依托单位:
Diagnosis and Monitoring of Glaucoma with Optical Coherence Tomography Angiography
-
批准号:10444613
-
项目类别:
-
资助金额:$69.56万
-
财政年份:2018
-
负责人:ROBERT N WEINREB
-
依托单位:
Ophthalmology and Visual Sciences Career Development K12 Program
-
批准号:8847895
-
项目类别:
-
资助金额:$22.67万
-
财政年份:2015
-
负责人:ROBERT N WEINREB
-
依托单位:
Ophthalmology and Visual Sciences Career Development K12 Program
-
批准号:9254555
-
项目类别:
-
资助金额:$64.02万
-
财政年份:2015
-
负责人:ROBERT N WEINREB
-
依托单位:
Ophthalmology and Visual Sciences Career Development K12 Program
-
批准号:10450760
-
项目类别:
-
资助金额:$49.34万
-
财政年份:2015
-
负责人:ROBERT N WEINREB
-
依托单位:
Ophthalmology and Visual Sciences Career Development K12 Program
-
批准号:9040968
-
项目类别:
-
资助金额:$43.98万
-
财政年份:2015
-
负责人:ROBERT N WEINREB
-
依托单位:
Ophthalmology and Visual Sciences Career Development K12 Program
-
批准号:10676982
-
项目类别:
-
资助金额:$49.34万
-
财政年份:2015
-
负责人:ROBERT N WEINREB
-
依托单位:
Ophthalmology and Visual Sciences Career Development K12 Program
-
批准号:10190539
-
项目类别:
-
资助金额:$49.34万
-
财政年份:2015
-
负责人:ROBERT N WEINREB
-
依托单位:
Sirtuins in Glaucomatous Optic Neuropathy
-
批准号:8389546
-
项目类别:
-
资助金额:$59.6万
-
财政年份:2011
-
负责人:ROBERT N WEINREB
-
依托单位:
Sirtuins in Glaucomatous Optic Neuropathy
-
批准号:8041809
-
项目类别:
-
资助金额:$59.58万
-
财政年份:2011
-
负责人:ROBERT N WEINREB
-
依托单位:
Sirtuins in Glaucomatous Optic Neuropathy
-
批准号:8204632
-
项目类别:
-
资助金额:$63.96万
-
财政年份:2011
-
负责人:ROBERT N WEINREB
-
依托单位:
EICOSANOIDS IN OUTFLOW PATHWAY OF EYE: GLAUCOMA
-
批准号:6247542
-
项目类别:
-
资助金额:$4.54万
-
财政年份:1997
-
负责人:ROBERT N WEINREB
-
依托单位:
QUANTITATIVE ANALYSIS OF OPTIC DISC/OCULAR HYPERTENSION
-
批准号:6384654
-
项目类别:
-
资助金额:$34.73万
-
财政年份:1995
-
负责人:ROBERT N WEINREB
-
依托单位:
QUANTITATIVE ANALYSIS OF OPTIC DISC/OCULAR HYPERTENSION
-
批准号:2165454
-
项目类别:
-
资助金额:$27.68万
-
财政年份:1995
-
负责人:ROBERT N WEINREB
-
依托单位:
QUANTITATIVE ANALYSIS OF OPTIC DISC/OCULAR HYPERTENSION
-
批准号:2444380
-
项目类别:
-
资助金额:$20.0万
-
财政年份:1995
-
负责人:ROBERT N WEINREB
-
依托单位:
QUANTITATIVE ANALYSIS OF OPTIC DISC/OCULAR HYPERTENSION
-
批准号:6804123
-
项目类别:
-
资助金额:$37.93万
-
财政年份:1995
-
负责人:ROBERT N WEINREB
-
依托单位:
QUANTITATIVE ANALYSIS OF OPTIC DISC/OCULAR HYPERTENSION
-
批准号:2711149
-
项目类别:
-
资助金额:$20.98万
-
财政年份:1995
-
负责人:ROBERT N WEINREB
-
依托单位:
QUANTITATIVE ANALYSIS OF OPTIC DISC/OCULAR HYPERTENSION
-
批准号:2165455
-
项目类别:
-
资助金额:$27.51万
-
财政年份:1995
-
负责人:ROBERT N WEINREB
-
依托单位:
Quantitative Analysis of Optic Disc/Ocular Hypertension
-
批准号:7122359
-
项目类别:
-
资助金额:$38.63万
-
财政年份:1995
-
负责人:ROBERT N WEINREB
-
依托单位:
QUANTITATIVE ANALYSIS OF OPTIC DISC/OCULAR HYPERTENSION
-
批准号:6518539
-
项目类别:
-
资助金额:$35.77万
-
财政年份:1995
-
负责人:ROBERT N WEINREB
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: